CME SEC Filings: 8-K, 10-Q, S-3 & 424B

Financials

TYPE

HEADLINE

FILED AT

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Oct 23, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Jul 24, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Apr 24, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Feb 26, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Oct 24, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Jul 24, 2025

News

TYPE

HEADLINE

FILED AT

8-K

CME Group Inc. Reports Highest Q3 Revenue on Record for Q3 2026

Oct 21, 2026

8-K

CME Group Inc. Files Certificate of Elimination for Series G Preferred Stock

Sep 25, 2026

8-K

CME Group Announces New Senior Leadership Appointments

Sep 9, 2026

8-K

CME Group Inc. Announces Pricing Changes

Aug 11, 2026

8-K

CME Group Inc. Reports Strong Financial Results for Q2 2026

Jul 22, 2026

8-K

CME Group CEO Terry Duffy to Transition to Executive Chairman in 2027; Lynne Fitzpatrick Named Successor

Jun 17, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B5

Form 424B5 - Prospectus [Rule 424(b)(5)]

Mar 4, 2025

424B5

Form 424B5 - Prospectus [Rule 424(b)(5)]

Mar 3, 2025

424B5

10,000,000 authorized shares of Preferred Stock, par value $.01 per share (the Preferred Stock).-

Mar 3, 2022

424B5

10,000,000 authorized shares of Preferred Stock, par value $.01 per share (the Preferred Stock).-

Mar 1, 2022

424B5

Class A Common Stock

Jun 15, 2018

424B5

Class A Common Stock

Jun 14, 2018

Registrations

TYPE

HEADLINE

FILED AT

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Mar 13, 2026

FWP

Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses

Mar 3, 2025

S-3ASR

Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers

Mar 3, 2025

S-8

Registration

Jun 9, 2022

FWP

$750,000,000

Mar 1, 2022

S-3ASR

10,000,000 authorized shares of Preferred Stock, par value $.01 per share (the Preferred Stock).-

Mar 1, 2022

Proxies

TYPE

HEADLINE

FILED AT

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

May 19, 2026

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 15, 2026

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Mar 23, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Mar 23, 2026

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Mar 12, 2026

PRE 14A

Form PRE 14A - Other preliminary proxy statements

Mar 12, 2026

Ownerships

TYPE

HEADLINE

FILED AT

144

NEWForm 144 - Report of proposed sale of securities

Nov 9, 2026

SIEGEL HOWARD J (Reporting)

Nov 3, 2026

Winkler Julie (Reporting)

Nov 2, 2026

Render Matthew V (Reporting)

Nov 2, 2026

144

Form 144 - Report of proposed sale of securities

Nov 2, 2026

144

Form 144 - Report of proposed sale of securities

Nov 2, 2026

Other

TYPE

HEADLINE

FILED AT

LETTER

Form UPLOAD - SEC-generated letter

Dec 1, 2025

CORRESP

Form CORRESP - Correspondence

Sep 25, 2025

LETTER

Form UPLOAD - SEC-generated letter

Sep 12, 2025

CORRESP

Form CORRESP - Correspondence

Feb 27, 2025

LETTER

Form UPLOAD - SEC-generated letter

Oct 25, 2022

CORRESP

Form CORRESP - Correspondence

Sep 30, 2022

CME Group Inc. CME · SEC Filings